Kedrion Announces An Eight-Year Extension Of The Distribution Agreement With Kamada In The U.S. For Kedrab
Portfolio Pulse from Benzinga Newsdesk
Kedrion Biopharma has extended its exclusive distribution agreement with Kamada Ltd. for KEDRAB®, a Human Rabies Immune Globulin (HRIG), in the U.S. for another eight years starting January 2024. The agreement also includes potential expansion of distribution in additional territories beyond the U.S. and collaboration to expand distribution of Kedrion products in Israel. KEDRAB® is part of the post-exposure prophylaxis for rabies, a significant public health concern globally and in the U.S., where an estimated 60,000 Americans receive treatment annually. The CEOs of both companies expressed confidence in the partnership's continued success in the U.S. market.
December 07, 2023 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kamada Ltd. has secured an eight-year extension of its U.S. distribution agreement with Kedrion for KEDRAB®, potentially expanding its market reach. This agreement is expected to bolster Kamada's presence in the U.S. and may contribute to future revenue growth.
The extension of the distribution agreement for KEDRAB® in the U.S. is likely to have a positive impact on Kamada's stock in the short term due to the potential for increased sales and market penetration. The confidence in the partnership expressed by both companies' CEOs and the mention of significant market share growth to date suggest a strong performance outlook for KMDA.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90